Table 1.

Association of SOX4 expression with the clinicopathological features of 136 patients with PGC

Factor	NO.	SOX4 expression (n, %)				P
		Negative	Weak	Moderate	Strong
Gender
Male	60	14 (23.3)	9 (15.0)	20 (33.3)	17 (28.3)	NS
Female	76	20 (22.2)	12 (15.8)	25 (32.9)	19 (25.0)
Age
≤ 66 years	65	16 (24.6)	10 (15.4)	21 (32.3)	18 (27.7)	NS
> 66 years	71	18 (25.4)	11 (15.5)	24 (33.8)	18 (25.4)
Tumor size
≤ 2.5 cm	72	19 (26.4)	12 (16.7)	25 (34.7)	16 (22.2)	NS
> 2.5 cm	64	15 (23.4)	9 (14.1)	20 (31.3)	20 (31.3)
Histological grade
G1	18	1 (5.6)	3 (16.7)	4 (22.2)	10 (55.6)	0.02
G2	72	13 (18.1)	3 (4.2)	32 (44.4)	24 (33.3)
G3	33	10 (30.3)	13 (39.4)	8 (24.2)	2 (6.1)
G4	13	10 (76.9)	2 (15.4)	1 (7.7)	0 (0.0)
Pathologic T stage
T1	22	2 (9.1)	2 (9.1)	6 (27.3)	12 (54.5)	0.02
T2	60	4 (6.7)	5 (8.3)	29 (48.3)	22 (36.7)
T3	36	16 (44.4)	10 (27.8)	8 (22.2)	2 (5.6)
T4	18	12 (66.7)	4 (22.2)	2 (11.1)	0 (0.0)
Clinical stage
I	46	4 (8.7)	6 (13.0)	16 (2.2)	20 (43.5)	0.03
II	52	8 (15.4)	4 (7.7)	25 (48.1)	15 (28.8)
III	18	10 (55.6)	5 (27.8)	2 (11.1)	1 (5.6)
IV	20	12(60.0)	6 (30.0)	2 (10.0)	0 (0.0)
Nodal metastasis
Negative	92	12 (13.0)	3 (3.3)	41 (44.6)	36 (39.1)	0.01
Positive	44	22 (50.0)	18 (40.9)	4 (9.1)	0 (0.0)
Distant metastasis
Negative	112	28 (25.0)	16 (14.3)	35 (31.3)	33 (29.5)	NS
Positive	24	6 (25.0)	5 (20.8)	10 (41.7)	3 (12.5)
Venous/lymphatic invasion
Negative	82	22 (26.8)	12 (14.6)	24 (29.3)	24 (29.3)	NS
Positive	54	12 (22.2)	9 (16.7)	21 (38.9)	12 (22.2)
Perineural invasion
Negative	79	20 (25.3)	12 (15.2)	24 (30.4)	23 (29.1)	NS
Positive	57	14 (24.6)	9 (15.8)	21 (36.8)	13 (22.8)

Note: 'NS' refers to 'No statistic significance'